Literature DB >> 12916903

Kinetics of paclitaxel 2'-N-methylpyridinium mesylate decomposition.

Jaber G Qasem1, Paul M Bummer, George A Digenis.   

Abstract

This study was designed to examine the kinetics of decomposition of paclitaxel 2'-N-methylpyridinium mesylate (PNMM), a derivative of paclitaxel. Further, the potential for PNMM to act as a prodrug of paclitaxel was assessed in vitro. Stability studies of PNMM were conducted over a pH range of 4.0 to 8.0 at 25 degrees C. The critical micelle concentration (CMC) of PNMM was determined by pulsating bubble surfactometry. Studies of the conversion of PNMM to paclitaxel were conducted in vitro in human plasma. Decomposition of PNMM followed apparent zero-order kinetics. The pH-rate profile exhibited no evidence of acid catalysis down to pH 4.0, while the rate was accelerated under base conditions. Surface tension studies suggested that PNMM formed micelles with a CMC of approximately 34 micro g/mL. Conversion studies in phosphate buffer showed that no more than 5% of PNMM converted to paclitaxel, while in human plasma the conversion was about 25%. The degradation of PNMM was via apparent zero-order kinetics and was dependent upon pH. The observed apparent zero-order kinetics of decomposition of PNMM was consistent with the formation of micelles in phosphate buffer. In buffered aqueous media alone or in human plasma, PNMM did not convert quantitatively to paclitaxel. Thus, the limiting factor in the application of PNMM as a prodrug would appear to be the poor potential to convert to paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12916903      PMCID: PMC2750599          DOI: 10.1208/pt040221

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  8 in total

1.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

Authors:  M C Wani; H L Taylor; M E Wall; P Coggon; A T McPhail
Journal:  J Am Chem Soc       Date:  1971-05-05       Impact factor: 15.419

2.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

Authors:  W P McGuire; E K Rowinsky; N B Rosenshein; F C Grumbine; D S Ettinger; D K Armstrong; R C Donehower
Journal:  Ann Intern Med       Date:  1989-08-15       Impact factor: 25.391

3.  Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity.

Authors:  H M Deutsch; J A Glinski; M Hernandez; R D Haugwitz; V L Narayanan; M Suffness; L H Zalkow
Journal:  J Med Chem       Date:  1989-04       Impact factor: 7.446

4.  Salt form selection and characterization of LY333531 mesylate monohydrate.

Authors:  G L Engel; N A Farid; M M Faul; L A Richardson; L L Winneroski
Journal:  Int J Pharm       Date:  2000-04-05       Impact factor: 5.875

5.  Modified taxols, 4. Synthesis and biological activity of taxols modified in the side chain.

Authors:  N F Magri; D G Kingston
Journal:  J Nat Prod       Date:  1988 Mar-Apr       Impact factor: 4.050

6.  Synthesis and evaluation of water-soluble paclitaxel prodrugs.

Authors:  Xia Feng; Ying-Jin Yuan; Jin-Chuan Wu
Journal:  Bioorg Med Chem Lett       Date:  2002-11-18       Impact factor: 2.823

7.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 8.  Taxol: an important new drug in the management of epithelial ovarian cancer.

Authors:  M Markman
Journal:  Yale J Biol Med       Date:  1991 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.